RxDoctor Payments Data

Elizabeth Romano

Nurse Practitioner · Indianapolis, INNPI 1487321345

Payments from drug & device makers

$4,040in general payments, 2019–2025

Across 154 payments — averaging $26.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$631
  • Novartis$397
  • Johnson & Johnson$221
  • AbbVie$218
  • Merck$201
  • Daiichi Sankyo Inc.$190
  • plus $2K from 43 others

What the payments were for

  • Food & beverage$3,79294%
  • Education$2486%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,040 in reported general payments places this provider in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$1,363
Medicare patients
18
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$13,490
XareltoRivaroxaban12$8,729
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen68$1,882
Morphine Sulfate ErMorphine Sulfate44$1,443
Oxycodone Hcl66$1,426
Ondansetron OdtOndansetron83$1,260
Anastrozole53$1,241
Dexamethasone37$895
Olanzapine35$841
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen34$656
Prochlorperazine Maleate50$655
Tramadol Hcl42$501
Tamoxifen Citrate14$389
Hydroxyurea13$388
Gabapentin37$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$112$13,49020 claims
Johnson & JohnsonXarelto$221$8,72912 claims
Lilly USA, LLCOlanzapine$39$84135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →